UroGen Pharma Ltd. (URGN)

Market Cap	425.37M
Revenue (ttm)	89.36M
Net Income (ttm)	-115.38M
Shares Out	42.20M
EPS (ttm)	-3.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	785,534
Open	10.83
Previous Close	10.71
Day's Range	10.08 - 10.86
52-Week Range	9.78 - 20.70
Beta	1.09
Analysts	Strong Buy
Price Target	42.25 (+319.15%)
Earnings Date	Mar 13, 2025

About URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate ris...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 201
• Stock Exchange: NASDAQ
• Ticker Symbol: URGN
• Website: https://www.urogen.com

Financial Performance

In 2023, UroGen Pharma's revenue was $82.71 million, an increase of 28.52% compared to the previous year's $64.36 million. Losses were -$102.24 million, -6.87% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price forecast is $42.25, which is an increase of 319.15% from the latest price.

Price Target

$42.25

(319.15% upside)

Analyst Consensus: Strong Buy